APA (7th ed.) Citation

(2021). Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

Chicago Style (17th ed.) Citation

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. 2021.

MLA (8th ed.) Citation

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. 2021.

Warning: These citations may not always be 100% accurate.